[go: up one dir, main page]

WO2021187905A1 - Composition pharmaceutique pour le traitement du cancer et du cancer résistant comprenant trichosanthes kirilowii maxim, dictamnus dasycarpus turcz et morus alba l. - Google Patents

Composition pharmaceutique pour le traitement du cancer et du cancer résistant comprenant trichosanthes kirilowii maxim, dictamnus dasycarpus turcz et morus alba l. Download PDF

Info

Publication number
WO2021187905A1
WO2021187905A1 PCT/KR2021/003335 KR2021003335W WO2021187905A1 WO 2021187905 A1 WO2021187905 A1 WO 2021187905A1 KR 2021003335 W KR2021003335 W KR 2021003335W WO 2021187905 A1 WO2021187905 A1 WO 2021187905A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
cancer
composition
chrysanthemum
sangbaekpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/003335
Other languages
English (en)
Korean (ko)
Inventor
고성규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Songheon R&d
Original Assignee
Songheon R&d
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Songheon R&d filed Critical Songheon R&d
Publication of WO2021187905A1 publication Critical patent/WO2021187905A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a composition
  • a composition comprising a mixed extract of chrysanthemum powder, tinea skin and sangbaekpi, which can be used as an anticancer agent or an anticancer adjuvant due to excellent anticancer effect on the survival of cancer cells and cancer cells induced by multi-drug resistance (MDR).
  • MDR multi-drug resistance
  • Targeted anticancer drugs developed to complement this are therapeutic substances that target specific molecules by discriminating only specific cancer cells.
  • Targeted anticancer drugs have the advantage of reducing the toxicity of existing chemotherapeutic agents, but can be used specifically for patients with specific target markers, and there is a possibility of drug resistance or recurrence due to continuous drug administration, such as chemotherapy.
  • Immunotherapy which has been recently developed and studied a lot, is a method of destroying cancer cells using the immune system of cancer patients. The burden is high, and there is a possibility of unexpected side effects.
  • MDR multi-drug resistance
  • the process by which cancer cells acquire resistance can be broadly divided into two categories.
  • One is extracellular resistance, where resistance occurs due to decreased delivery of anticancer drugs to cancer cells. in case it is not exposed.
  • the other is intracellular resistance through genetic mutation of cancer cells themselves. Although cancer cells are exposed to a sufficient concentration of an anticancer agent, resistance can be induced by reducing drug absorption and promoting release, mutation of drug metabolism, mutation of drug target, and activation of damage repair mechanism.
  • ABC transporter membrane receptor protein ATP-binding cassette
  • the present inventors have screened and confirmed various herbal substances to develop a novel composition for inhibiting multidrug resistance, and as a result, the mixed extract of chrysanthemum powder and tinea dermatophyte, and the extract mixed with sangbaekpi induced anticancer effect and resistance to general cancer cells.
  • the present invention was completed by confirming that it had the effect of inhibiting the cell viability of one cancer cell.
  • an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cancer, comprising chrysanthemum powder and ringworm.
  • Another object of the present invention is to provide a food or functional food composition for the prevention or suppression of cancer, including chrysanthemum powder and ringworm.
  • Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of multidrug-resistant cancer comprising chrysanthemum powder and ringworm.
  • Another object of the present invention is to provide a food or functional food composition for the prevention or inhibition of multidrug-resistant cancer, including chrysanthemum powder and ringworm.
  • Another object of the present invention is to provide a pharmaceutical composition for adjuvant anticancer comprising chrysanthemum powder and ringworm.
  • Another object of the present invention is to provide a food composition for adjuvant anti-cancer comprising chrysanthemum powder and ringworm skin.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of cancer comprising a chrysanthemum powder and ringworm skin.
  • the present invention provides a food or functional food composition for the prevention or suppression of cancer, including chrysanthemum powder and ringworm.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of multidrug-resistant cancer comprising chrysanthemum powder and ringworm.
  • the present invention is to provide a food or functional food composition for the prevention or inhibition of multidrug-resistant cancer containing chrysanthemum powder and ringworm.
  • the present invention provides a pharmaceutical composition for adjuvant anti-cancer comprising chrysanthemum powder and tinea skin.
  • the present invention provides a food composition for adjuvant anti-cancer comprising chrysanthemum powder and ringworm skin.
  • composition of the present invention may include a sangbaekpi extract in addition to the chrysanthemum powder and tinea extract, and the use thereof is the same.
  • the present invention relates to a pharmaceutical composition, a food or functional food composition, and an anticancer adjuvant composition comprising a mixed extract of chrysanthemum pollen, tinea skin and sangbaekpi, which has excellent anticancer and multi drug resistance (MDR) inhibitory effects, and the mixture
  • MDR multi drug resistance
  • the mixed extract of the present invention may be used alone or in combination with other anticancer substances.
  • HCC-827 a lung cancer cell
  • HCC-827/Gefitinib a multidrug-resistant cancer cell
  • 3 and 4 are results of analysis of the effect of a 2:1 combination of chrysanthemum pollen and tinea skin on the survival rate of MCF-7, a breast cancer cell, and MCF-7/Dox, a multidrug-resistant cancer cell, through MTT assay.
  • 5 and 6 show the results of analysis through MTT assay of the effect of a 1:1:1 combination of chrysanthemum pollen, sangbaekpi, and tinea skin on the survival rate of MCF-7, a breast cancer cell, and MCF-7/Dox, a multidrug-resistant cancer cell. am.
  • FIG. 7 and 8 show the results of analysis through MTT assay of the effect of a 2:1 combination of chrysanthemum pollen and tinea skin on the survival rate of HCC-827, a lung cancer cell, and HCC-827/Gefitinib, a multidrug-resistant cancer cell.
  • 11 and 12 show that a combination of various ratios (1:1, 2:1, 1:2) of single herbal medicines, Cheonhwabun, Sangbaekpi, and chrysanthemum, and Cheonhwabun and tinea, Cheonhwabun and Sangbaekpi, and Sangbaekpi and tinea cortex, are breast cancer cells. and the result of analyzing the effect on the survival rate of breast cancer-resistant cancer cells by MTT assay.
  • 13 and 14 show that the combination of various ratios (1:1, 2:1, 1:2) of one herbal medicine, Cheonhwabun, Sangbaekpi, and tinea dermatophyte, and Cheonhwabun and tinea cortex, Cheonhwabun and sangbaekpi and Sangbaekpi and tinea dermatophyte, is a combination of lung cancer cells. and the result of analyzing the effect on the survival rate of lung cancer-resistant cancer cells by MTT assay.
  • 15 and 16 show various ratios (2:1:1, 1:2:1, 1:1:2, 5:1:1, The effect of 1:5:1, 1:1:5, 10:1:1, 1:10:1, 1:1:10) combinations on the inhibition of survival rates of breast cancer cells and resistant breast cancer cell lines was evaluated by MTT assay. It is the result of analysis.
  • 17 and 18 show various ratios (2:1:1, 1:2:1, 1:1:2, 5:1:1, The effect of 1:5:1, 1:1:5, 10:1:1, 1:10:1, 1:1:10) combinations on the inhibition of survival rates of lung cancer cells and resistant lung cancer cell lines was evaluated by MTT assay. It is the result of analysis.
  • FIG. 21 shows the results of Rhodamine 123 assay of breast cancer-resistant cancer cells by treating a single herbal medicine, cheonhwabun, a combination of cheonhwabun, sangbaekpi, and baekseonpi.
  • Figure 22 shows the results of analysis through MTT assay to see if the synergistic effect of treating breast cancer-resistant cancer cells with Doxorubicin in combination with a combination of cheonhwabun, cheonhwabun, sangbaekpi, and tinea derma, which are single herbal medicines, is shown.
  • the present invention relates to a pharmaceutical and food composition
  • a pharmaceutical and food composition comprising, as an active ingredient, a mixed extract of chrysanthemum powder and chrysanthemum powder having an effect of preventing, treating, or inhibiting cancer, or a mixed extract containing sangbaekpi as an active ingredient.
  • the cancer is not limited to the type, and oral cancer, stomach cancer, lung cancer, breast cancer, ovarian cancer, liver cancer , bronchogenic cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, cervical cancer, brain cancer ( brain cancer, prostate cancer, bone cancer, skin cancer, thymus cancer, parathyroid cancer, renal cancer or ureter cancer .
  • the composition of the present invention has an effect of inhibiting the growth of the cancer cells, and in particular includes an anticancer effect on resistant cancer cells induced in resistance to a therapeutic agent among the cancers.
  • multidrug resistance refers to the property of a cell, particularly a specific disease-causing cell, to be resistant to various drugs or compounds having a very different chemical structure.
  • the term multi-drug resistance drug of the present invention includes, for example, vinca alkaloids, vinblastine, vincristine, and navelbine; Paclitaxel (TAX), taxotere (taxotere) of the taxanes family; doxorubicin, daunorubicin, epirubicin and idarubicin from the anthracyclines class; Epipodophyllotoxins, etoposide and teniposide, colchicine, mitoxantrone, dactinomycin, topotecan, trimet other drugs such as trimetrexate, mithramycin, and mitomycin C.
  • Paclitaxel TAX
  • taxotere taxotere
  • doxorubicin daunorubicin
  • epirubicin and idarubicin from the anthracyclines class
  • Epipodophyllotoxins etoposide and teniposide, colchicine, mitoxantrone, dact
  • the multi-drug resistance inhibitory efficacy of the composition of the present invention is characterized in that the multi-drug resistance inhibitory efficacy in cancer cells.
  • the survival and growth inhibitory effects of single or mixed extracts of chrysanthemum pollen, sangbaekpi and tinea cortex of the present invention were confirmed on the survival and growth inhibition of general cancer cells and resistant cancer cells.
  • the inhibitory activity of P-glycoprotein (P-gp) was confirmed in cancer cells that induced multidrug resistance. From this, it was experimentally confirmed that the extract of the present invention can have an anticancer effect on resistant cancer cells induced with anticancer activity and multi-drug resistance against general cancer cells.
  • cheonhwabun Trichosanthes kirilowii Maxim
  • Gwalugeun ⁇
  • Sangbaekpi Morus alba L
  • sangbaekpi is effective in treating asthma caused by pulmonary blood, diuretic, blood pressure lowering and anti-inflammatory.
  • Ringworm ( Dictamnus dasycarpus Turcz. ) is the root bark of ringworm belonging to the family Urumaceae. Ringworm is used as a treatment when the skin breaks down and a rash occurs, and its representative pharmacological action is antipyretic action and skin fungal suppression action. Dictamnine, dictamnoside, and limonin are known as the main components of tinea skin, and studies on the antioxidant and antibacterial effects of tinea skin have been reported.
  • the mixed extract contained in the composition of the present invention includes a mixed extract containing the cheonhwabun and sangbaekpi, and a mixed extract including the cheonflowerbun, sangbaekpi and tinea phyllis.
  • each drug is pulverized after washing with water and extracted for about 1 to 10 hours with a solvent in a volume equivalent to 1 to 50 times the weight of each raw material.
  • the extract includes an extract obtained by extraction treatment, a dilution thereof, a concentrate, a dried product of the extract, and a purified product thereof.
  • the extraction method is not particularly limited and may be extracted through various extraction methods known in the art, such as heat extraction, pressure extraction, ultrasonic extraction, reflux circulation extraction, ultrasonic extraction, and supercritical extraction method.
  • the type of the solvent used for the extraction is not particularly limited, and various solvents are used as necessary, and may include, for example, water, ethanol, methanol, lower alcohol such as alcohol, and the like.
  • a conventional method in the art may be used, such as cold immersion, warm immersion, and heating using the solvent.
  • extracts were obtained using 70% ethanol for the extracts of chrysanthemum pollen, sangbaekpi and baekseonpi. Since the active ingredient of the raw material may have different extraction efficiency depending on the polarity of the solvent, in order to maximize the content of the active ingredient contained in the raw material, the type and concentration of the extraction solvent may be changed.
  • the mixed extract of the present invention may contain each of the extract of chrysanthemum powder and chrysanthemum in a ratio of 0.2 to 5:1, and more preferably 0.5 to 2:1.
  • the mixing ratio is not particularly limited, but may be included in a weight ratio of 1 to 10: 1 to 10: 1 to 10.
  • the content is a range having the effects of preventing and treating cancer, and preventing and treating resistant cancer suggested in the present invention, and there is a possibility that the effect may be different depending on the mixing ratio of the raw materials.
  • the mixing ratio can be controlled to an appropriate level so that effects such as anticancer and resistant cancer suppression by the active ingredient are appropriately implemented.
  • composition of the present invention may be formulated as a pharmaceutical composition (including anticancer adjuvant) for the prevention and treatment of cancer or multidrug-resistant cancer.
  • additives such as commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, diluents and excipients may be additionally included, and one or more pharmaceutically acceptable carriers are included. can be manufactured.
  • Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
  • a lubricant e.g., a talc, a kaolin, a kaolin, a kaolin, a kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, a talct, a talct, a talct, a talct, a sorbitol, mannitol, mannitol
  • an effective dosage may vary depending on the patient's age, weight, sex, dosage form, health status and disease degree, and is generally about 0.001-100 mg/kg/day, preferably It is usually 0.01-35 mg/kg/day. Based on an adult patient weighing 70 kg, it is generally 0.07-7000 mg/day, preferably 0.7-2500 mg/day, and once a day at regular time intervals according to the judgment of a doctor or pharmacist It can be administered in divided doses.
  • composition of the present invention may be formulated as an anticancer adjuvant.
  • Anticancer adjuvant is used to increase the anticancer effect of an anticancer agent, suppress the side effects of the anticancer agent, or, in the case of cancer cells having resistance to the anticancer agent, further enhance or improve the anticancer effect.
  • an anticancer adjuvant it may be administered as a single agent, but in general, it may be administered in combination with an anticancer agent.
  • the effect on the anticancer drug sensitivity was confirmed.
  • the extract of the present invention includes use as an anticancer adjuvant that can overcome anticancer drug resistance.
  • the composition of the present invention may also be formulated as a food or functional food composition.
  • a food or functional food containing the mixed extract containing the turmeric powder, sangbaekpi and baekseonpi of the present invention as an active ingredient the type is not particularly limited.
  • foods that may contain the mixed extract of the present invention include drinks, beverages, tea, meat, sausages, biscuits, rice cakes, chocolate, candy, jellies, snacks, confectionery, ramen, noodles, gums, dairy products, vitamins It can be used as a combination agent, other processed foods and additives, and includes all foods or functional foods in a general sense.
  • the health functional food and health food composition containing the mixed extract according to the present invention may be added to food as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the mixed extract of the present invention may be suitably determined according to the purpose of its use (for prevention or improvement).
  • the amount of the composition in the health functional food and health food may be added in an amount of 0.1 to 90 parts by weight based on the total weight of the food.
  • the amount may be less than the above range, and since there is no problem in terms of safety, the mixed extract may be used in an amount above the above range.
  • the food or functional food composition containing the mixed extract of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, colorants and thickeners (cheese, chocolate, etc.), pects acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
  • the health functional food and health food composition of the present invention may contain natural fruit juice, fruit juice, and fruit for the production of fruit juice drinks and vegetable drinks.
  • the above components may be used independently or in combination.
  • the proportion of the additive is not limited thereto, but may be selected from 0.1 to 50 parts by weight per 100 parts by weight of the whole food or functional food composition.
  • turmeric powder Trichosanthes kirilowii Maxim
  • ringworm Dictamnus dasycarpus Turcz
  • 70% ethanol 70% ethanol
  • Plant pollen Trichosanthes kirilowii Maxim ), Sangbaekpi ( Morus alba L), and Ringworm ( Dictamnus dasycarpus Turcz ) were 1:1:1, 2:1:1, 1:2:1, 1:1:2, 5:1, respectively. :1, 1:5:1, 1:1:5, 10:1:1, 1:10:1, 1:1:10 after mixing in a weight ratio (w/w), put in an extractor, 70% each After each addition of ethanol, extraction was performed for 2-3 hours. The extract was filtered, the filtrate was concentrated under reduced pressure, and dried to obtain a mixed extract (70% ethanol extract) of chrysanthemum powder, sangbaekpi, and baekseonpi.
  • a mixed extract 70% ethanol extract
  • the breast cancer-resistant cancer cell line used in the present invention was an MCF-7 breast cancer cell line (MCF-7/Dox) having doxorubin resistance. This cell line was provided by Professor Hwajeong Lee of Ewha Mans University (Ref. Phytother Res, 30 (12), 2020-2026). A lung cancer-resistant cancer cell line was used as a gefitinib-resistant HCC-827 lung cancer cell line (HCC-827/GR). The gefitinib-resistant cell line was provided by researcher Jeong Seong-geun of the Korea Food Research Institute and used.
  • the breast cancer cell line MCF-7 and the breast cancer cell line MCF-7/Dox inducing multidrug resistance of the mixed extract (extract B) prepared in Example 1 in a 1:1:1 ratio of chrysanthemum pollen, sangbaekpi, and chrysanthemum Cell viability was analyzed. After each cell line was treated with the extract A at a concentration of 10 to 500 ⁇ g/ml for 48 hours, cell viability was analyzed by MTT Assay.
  • the lung cancer cell line HCC-827 and the lung cancer cell line HCC-827/GR that induced multidrug resistance of the mixed extract (extract B) prepared in Example 1 in a 1:1:1 ratio of chrysanthemum pollen, sangbaekpi, and chrysanthemum Cell viability was analyzed.
  • extract B was treated at a concentration of 10 to 500 ⁇ g/ml for 48 hours in each cell line, cell viability was analyzed by MTT Assay.
  • the mixed extract of the present invention had an effect of suppressing the survival rate in both general breast cancer cell lines and multidrug-resistant cancer cell lines, compared to the single extract.
  • the mixed extract in which chrysanthemum pollen and ringworm were mixed in a ratio of 2:1 showed the most excellent cell viability inhibitory effect in both normal and resistant cancer cells.
  • a single extract of each plant pollen, sangbaekpi, and chrysanthemum, 1:1:1, 2:1:1, 1:2:1, 1:1:2, 5:1:1, 1:5 Inducing breast cancer cell lines, lung cancer cell lines, and multidrug-resistant cancer by preparing a mixed extract mixed at a ratio of :1, 1:1:5, 10:1:1, 1:10:1, 1:1:10, respectively After each cancer cell line was treated at a concentration of 250 ⁇ g/ml and 500 ⁇ g/ml for 48 hours, each cell survival inhibition rate was analyzed by MTT Assay.
  • the mixed extract of the present invention had an effect of suppressing the survival rate in both general breast cancer cell lines and multidrug-resistant cancer cell lines, compared to the single extract.
  • the mixed extract in which chrysanthemum pollen, sangbaekpi, and chrysanthemum were mixed in a ratio of 1:1:1 it was confirmed that the cell viability inhibitory effect was the most excellent in both normal and resistant cancer cells.
  • HCC-827 a lung cancer cell line, and HCC-827/GR, a lung cancer cell line that induces multidrug resistance, it is known that intracellular signaling by EGFR is very active due to mutations in the EGFR gene. Therefore, it is important to inhibit the EGFR signaling system as a therapeutic method.
  • the mixed extract mixed with a 1:1:1 ratio of chrysanthemum pollen, sangbaekpi and chrysanthemum powder and a 2:1 ratio of chrysanthemum pollen and chrysanthemum powder was EGFR phosphorylated (Tyr 1068, Tyr). 1173) was confirmed to be further inhibited. In addition, it was confirmed that phosphorylation of AKR, a sub-signaling mechanism of EGFR, was inhibited.
  • the breast cancer resistant cell line was treated at a concentration of 500 ⁇ g/ml for 24 hours, followed by rhodamine 123 (1 ⁇ g/ml) was reacted for 1 hour. After the reaction, cells were collected and rhodamine 123 activity was measured using flow cytometry.
  • Rhodamine 123 is a fluorescent substance that can move in and out of cells by P-gp, and its ability to excrete rhodamine 123 is determined by the function of P-gp. That is, since rhodamine 123 is released out of the cell by P-gp, it can be seen that when the accumulation of rhodamine 123 in the cell increases, the function of P-gp is suppressed.
  • MTT assay was performed to determine whether the mixed extract of chrysanthemum pollen, sangbaekpi, and tinea dermata increased the sensitivity of anticancer drugs in breast cancer and lung cancer cell lines that induced multidrug-resistant cancer.
  • a mixed extract of chrysanthemum pollen, sangbaekpi and tinea skin and anticancer drugs Doxorubicin, Gefitinib were co-treated for 48 hours.
  • the mixed extracts of chrysanthemum pollen, sangbaekpi, and chrysanthemum were treated at concentrations of 100, 250, and 500 ⁇ g/ml, and Doxorubicin and Gefitinib were tested at concentrations of 0.5, 1, 5, and 10 ⁇ g and 0.01, 0.1 and 1 ⁇ M, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait mixte de Trichosanthes kirilowii Maxim, Dictamnus dasycarpus Turcz et Morus alba L., ayant un excellent effet d'inhibition de la survie de cellules cancéreuses et de cellules cancéreuses ayant une résistance à de multiples médicaments (MDR) et, par mélange de l'extrait dans un rapport approprié, la composition peut être utilisée en tant qu'agent anticancéreux, inhibiteur de résistance à de multiples médicaments et adjuvant anticancéreux.
PCT/KR2021/003335 2020-03-20 2021-03-18 Composition pharmaceutique pour le traitement du cancer et du cancer résistant comprenant trichosanthes kirilowii maxim, dictamnus dasycarpus turcz et morus alba l. Ceased WO2021187905A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200034559A KR102434881B1 (ko) 2020-03-20 2020-03-20 천화분, 백선피 및 상백피를 포함하는 암 및 내성암에 대한 약학적 조성물
KR10-2020-0034559 2020-03-20

Publications (1)

Publication Number Publication Date
WO2021187905A1 true WO2021187905A1 (fr) 2021-09-23

Family

ID=77771568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/003335 Ceased WO2021187905A1 (fr) 2020-03-20 2021-03-18 Composition pharmaceutique pour le traitement du cancer et du cancer résistant comprenant trichosanthes kirilowii maxim, dictamnus dasycarpus turcz et morus alba l.

Country Status (2)

Country Link
KR (2) KR102434881B1 (fr)
WO (1) WO2021187905A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116621891A (zh) * 2023-05-25 2023-08-22 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009046391A (ja) * 2005-07-06 2009-03-05 Takehito Kono 悪液質改善治療製剤および悪液質改善作用を有する食品製剤
KR20120124151A (ko) * 2011-05-03 2012-11-13 경희대학교 산학협력단 상백피 추출물을 유효성분으로 포함하는 다중약물내성 억제용 조성물
KR20120124142A (ko) * 2011-05-03 2012-11-13 경희대학교 산학협력단 백선피 추출물을 유효성분으로 포함하는 다중약물내성 억제용 조성물
KR20120124508A (ko) * 2011-05-03 2012-11-14 경희대학교 산학협력단 천화분 추출물을 유효성분으로 포함하는 다중약물내성 억제용 조성물
KR20140145087A (ko) * 2013-06-11 2014-12-22 경희대학교 산학협력단 혼합 생약 추출물을 유효성분으로 포함하는 항암용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009046391A (ja) * 2005-07-06 2009-03-05 Takehito Kono 悪液質改善治療製剤および悪液質改善作用を有する食品製剤
KR20120124151A (ko) * 2011-05-03 2012-11-13 경희대학교 산학협력단 상백피 추출물을 유효성분으로 포함하는 다중약물내성 억제용 조성물
KR20120124142A (ko) * 2011-05-03 2012-11-13 경희대학교 산학협력단 백선피 추출물을 유효성분으로 포함하는 다중약물내성 억제용 조성물
KR20120124508A (ko) * 2011-05-03 2012-11-14 경희대학교 산학협력단 천화분 추출물을 유효성분으로 포함하는 다중약물내성 억제용 조성물
KR20140145087A (ko) * 2013-06-11 2014-12-22 경희대학교 산학협력단 혼합 생약 추출물을 유효성분으로 포함하는 항암용 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116621891A (zh) * 2023-05-25 2023-08-22 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用
CN116621891B (zh) * 2023-05-25 2023-10-31 齐齐哈尔医学院 白鲜酚苷c及其制备方法和其应用

Also Published As

Publication number Publication date
KR20210117802A (ko) 2021-09-29
KR102434881B1 (ko) 2022-08-23
KR20220119335A (ko) 2022-08-29

Similar Documents

Publication Publication Date Title
EP2044935B1 (fr) Composition contenant des cannabinoïdes non psychotropes pour le traitement de maladies inflammatoires
JP2024105626A (ja) エフェドリンアルカロイド除去麻黄エキスと、その製法及び用途
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
WO2021187905A1 (fr) Composition pharmaceutique pour le traitement du cancer et du cancer résistant comprenant trichosanthes kirilowii maxim, dictamnus dasycarpus turcz et morus alba l.
CN101181285A (zh) 黄芪甲苷在制备治疗神经退行性疾病药物中的应用
WO2018080157A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif
WO2012108748A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait d'albizzia julibrissin
US20230398168A1 (en) Use of effective part extract of monochasma savatieri in preparation of drug for treating inflammatory disease or tumor
KR102496753B1 (ko) 좁쌀풀 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물
WO2012108747A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de la racine d'helena
CN106176711A (zh) 包含类黄酮化合物组合物的药物及其应用
WO2012108743A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait des graines de pharbitis blanc
KR102671544B1 (ko) 복합 한약재 추출물을 유효성분으로 포함하는 스트레스 완화 및 면역증진용 조성물
WO2012108746A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de racine de rubia cordifolia
KR20200104016A (ko) 한속단으로부터 분리된 화합물을 포함하는 암 예방 또는 치료용 약학 조성물
WO2012108744A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de la fleur inula
WO2019225845A1 (fr) Composition pour soulager le méningiome en utilisant le salidroside et la bétuline
WO2018056772A1 (fr) Composition antitumorale ou composition induisant une immunité antitumorale comprenant un extrait d'erysimum sp. en tant qu'ingrédient efficace
Kemper Cat’s Claw (Uncaria tomentosa)
KR20240073178A (ko) 부채마 추출물 또는 디오신을 포함하는 기억력 개선, 신경염증 억제, 신경세포 사멸 억제, 또는 자가포식작용 촉진용 조성물
WO2023204364A1 (fr) Composition permettant la prévention, l'amélioration ou le traitement de maladies respiratoires allergiques comprenant un extrait d'alpinia officinarum hance en tant que principe actif
KR20020073237A (ko) 세신추출물을 함유하는 뇌세포 보호 및 기억력 증진용조성물
CN121154749A (en) Traditional Chinese medicine composition for treating depression and preparation method thereof
WO2012108742A2 (fr) Composition et l'alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de fleur tussilago farfara
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21771003

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21771003

Country of ref document: EP

Kind code of ref document: A1